

Endometriosis Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics), By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, And Others), By Treatment Method (Hormonal Therapy, And Pain Management), By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, And Others), By Diagnostics Type (Pure Medical Imaging, And General Laboratory Use), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By End-User, (Hospitals & Clinics, Ambulatory Care Center, And Others), By Company, By Region

<https://marketpublishers.com/r/EE52BCBBF963EN.html>

Date: November 2022

Pages: 111

Price: US\$ 4,900.00 (Single User License)

ID: EE52BCBBF963EN

Abstracts

The global endometriosis therapeutics market is expected to increase appreciably through 2027. Endometriosis is a disorder characterized by the tissues like the covering of the uterus growing on the outer part of the uterus. It is a type of chronic disease led to serve life-impacting pains during periods, sexual intercourse, urination, chronic pelvic pain, abdominal bloating, nausea, and fatigue. Sometimes extreme levels of these

disorders can result in depression, anxiety, and infertility. Across the globe, various initiatives are going to make people, majorly women, aware of the problem; there are many off-label practices due to lack of information. In developing countries, the cost of therapy is creating restraint in growth.

According to WHO, almost 10% of reproductive-age women will be affected by this syndrome or disease globally in 2021. Different government organizations and NGOs are running global campaigns to create Awareness. Launching new advanced products and therapies, Awareness about continuous improvement in patients, and improvement in non-invasive diagnostic methods are one of the major factors responsible for the market. Thus, we can expect a rise in growth and demand in the market share of Endometriosis therapeutics in 2027.

Growing Awareness About the Disease and Treatment in Society

The increasing pervasiveness of gynecological and chronic diseases, an increasing number of people suffering from endometriosis, ongoing R&D activities for advanced endometriosis treatment, and rising demand for hormonal therapies & novel drugs are factors responsible for the growth of the Endometriosis Therapeutics Market. As the population increases, the demand for medical treatment and equipment is increasing in various parts of the world. According to the WHO report, in 2021, almost 190 million reproductive women and girls will be affected by endometriosis worldwide. The above data shows that there is massive potential in the market as the number of potential customers is in the millions and continues its grow as the population increases in developing countries; patients are still not aware of endometriosis and take the wrong drugs and treatment when there are any health problems. Thus, different initiatives and awareness program are going on through social media, Online platforms, newspapers, and other means. Therefore, growing awareness about endometriosis can positively impact the market share.

The large number of women worldwide suffering from endometriosis led to increased demand for treatment. Due to its positive outcome, patients are suggesting the treatment to another patient, and this word of mouth are most impactful in term of awareness. Hence, this factor can positively impact the market share. These increasing demands make the player work for significant technological Advancement in therapeutics and improving treatment. Technological Advancement in segments helps the doctor to treat the patient with minimal surgical cuts on the body, less painful processes, and shorter recovery time. All these efforts make the method more in demand and market share.

Various community, government, and community initiatives are running to uplift women's health. Australia has funded 58 million for improving endometriosis under the national action plan. Janani Shishu Suraksha Yojana, National action plan, Women's health alliance is an example of global initiatives. These policies led to increasing demand for endometriosis therapeutics in the market. All the factors mentioned above are expected to drive the growth of the Endometriosis Therapeutics Market.

Off-Label Medication Practices are Hurdle in Growth

After so many awareness campaigns are running over the world, many people are still not reachable. Forget about the treatment. They are unaware of endometriosis and take treatment for another problem. Apart from this, in poorer countries, therapy costs are costly that restrain the market growth.

Continuous R&D for Advance Drug Technology is Driving Growth

The evolution of methods and drugs due to technological advancement per market requirements is expected to create impressive growth in the Endometriosis Therapeutics Market. Market players are proposing novel transdermal drug delivery technologies such as topical applicators to overcome the side effects of oral contraceptives and improve efficiency as many women sufferings from endometriosis increase the demand for treatment.

In 2022, Myovant science Limited and Pfizer LLC. Is collaborate and continued to jointly commercialize MYFEMBREE. This medicine is expected to help both companies combine their expertise to deliver the drug quickly and gain market size.

In 2022, Astellas Pharma Inc. announced the outcome of the drug, which is clinical trial version Phase 3, "SKYLIGHT 4". It is a non-hormonal composite studied for treating sensible to severe vasomotor symptoms associated with menopause (VMS) which will encourage future regulatory organizing submissions.

Market Segmentation

The global endometriosis therapeutics market is segmented based on endometriosis type, diagnostic method, therapeutic method, distribution channel, and end user type. Based on endometriosis type, market is divided into superficial peritoneal lesion, endometrioma, deeply infiltrating endometriosis therapeutics. Based on diagnostic

method, market is divided into ultrasound, pelvic examination, laparoscopy, magnetic resonance imaging, and others. Based on treatment method, market is split into hormonal therapy, and pain management. Based on drug category, market is divided into oral contraceptives, progestins, NSAIDs, GnRH analogues, and others. Based on diagnostics type, market is split into pure medical imaging v/s general laboratory use. Based on distribution channel, market is divided into retail pharmacies, hospital pharmacies, online pharmacies. Based on end user, market is divided into hospitals & clinics, ambulatory care center, and others, by company.

Market Players

The Abbott Laboratories, Inc. ; AbbVie, Inc.; Bayer AG; Pfizer, Inc.; Ipsen SA; Evotec SE; Myovant Sciences Ltd.; Philogen S.p.A.; Astellas Pharma Inc.; Orphagen Pharmaceuticals, Inc. are the major market player operating in the Endometriosis Therapeutics Market.

Report Scope:

In this report, global Endometriosis Therapeutics Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Endometriosis Therapeutics Market, by endometriosis type:

Superficial Peritoneal Lesion

Endometrioma

Deeply Infiltrating Endometriosis Therapeutics

Endometriosis Therapeutics Market, by diagnostic method:

Ultrasound

Pelvic Examination

Laparoscopy

Magnetic Resonance Imaging

Others

Endometriosis Therapeutics Market, by treatment method:

Hormonal Therapy

Pain Management

Endometriosis Therapeutics, by drug category:

Oral Contraceptives

Progestins

NSAIDs

GnRH Analogues

Others

Endometriosis Therapeutics, by distribution channel:

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Endometriosis Therapeutics Market, by end user type:

Hospitals & Clinics

Ambulatory Care Center

Others

Medical market, By Region:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

Australia

South Korea

Europe & CIS

Germany

France

United Kingdom

Spain

Italy

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Endometriosis Therapeutics Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. IMPACT OF COVID-19 ON GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET

4. VOICE OF CUSTOMER

5. EXECUTIVE SUMMARY

6. CLINICAL TRIAL ANALYSIS

7. GLOBAL ENDOMETRIOSIS THERAPEUTICS MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)

7.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)

7.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)

7.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)

7.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

7.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

7.2.6. By Region

7.2.7. By Company (2021)

7.3. Product Market Map

8. NORTH AMERICA ENDOMETRIOSIS THERAPEUTICS MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)

8.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)

8.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)

8.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)

8.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

8.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

8.2.6. By Country

8.3. North America: Country Analysis

8.3.1. United States Endometriosis Therapeutics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Endometriosis Type

8.3.1.2.2. By Diagnostic Method

8.3.1.2.3. By Therapeutic Method

8.3.1.2.4. By Distribution Channel

8.3.1.2.5. By End User

8.3.2. Mexico Endometriosis Therapeutics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Endometriosis Type

8.3.2.2.2. By Diagnostic Method

8.3.2.2.3. By Therapeutic Method

8.3.2.2.4. By Distribution Channel

8.3.2.2.5. By End User

8.3.3. Canada Endometriosis Therapeutics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Endometriosis Type

8.3.3.2.2. By Diagnostic Method

8.3.3.2.3. By Therapeutic Method

8.3.3.2.4. By Distribution Channel

8.3.3.2.5. By End User

9. EUROPE ENDOMETRIOSIS THERAPEUTICS MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)

9.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)

9.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)

9.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)

9.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

9.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

9.2.6. By Country

9.3. Europe: Country Analysis

9.3.1. France Endometriosis Therapeutics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Endometriosis Type

9.3.1.2.2. By Diagnostic Method

9.3.1.2.3. By Therapeutic Method

9.3.1.2.4. By Distribution Channel

9.3.1.2.5. By End User

9.3.2. United Kingdom Endometriosis Therapeutics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Endometriosis Type

9.3.2.2.2. By Diagnostic Method

9.3.2.2.3. By Therapeutic Method

9.3.2.2.4. By Distribution Channel

9.3.2.2.5. By End User

9.3.3. Italy Endometriosis Therapeutics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

- 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Endometriosis Type
 - 9.3.3.2.2. By Diagnostic Method
 - 9.3.3.2.3. By Therapeutic Method
 - 9.3.3.2.4. By Distribution Channel
 - 9.3.3.2.5. By End User
- 9.3.4. Germany Endometriosis Therapeutics Market Outlook
 - 9.3.4.1. Market Size & Forecast
 - 9.3.4.1.1. By Value
 - 9.3.4.2. Market Share & Forecast
 - 9.3.4.2.1. By Endometriosis Type
 - 9.3.4.2.2. By Diagnostic Method
 - 9.3.4.2.3. By Therapeutic Method
 - 9.3.4.2.4. By Distribution Channel
 - 9.3.4.2.5. By End User
- 9.3.5. Spain Endometriosis Therapeutics Market Outlook
 - 9.3.5.1. Market Size & Forecast
 - 9.3.5.1.1. By Value
 - 9.3.5.2. Market Share & Forecast
 - 9.3.5.2.1. By Endometriosis Type
 - 9.3.5.2.2. By Diagnostic Method
 - 9.3.5.2.3. By Therapeutic Method
 - 9.3.5.2.4. By Distribution Channel
 - 9.3.5.2.5. By End User

10. ASIA-PACIFIC ENDOMETRIOSIS THERAPEUTICS MARKET OUTLOOK

- 10.1. Market Size & Forecast
 - 10.1.1. By Value
- 10.2. Market Share & Forecast
 - 10.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
 - 10.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
 - 10.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
 - 10.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
 - 10.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

10.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

10.2.6. By Country

10.3. Asia-Pacific: Country Analysis

10.3.1. China Endometriosis Therapeutics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Endometriosis Type

10.3.1.2.2. By Diagnostic Method

10.3.1.2.3. By Therapeutic Method

10.3.1.2.4. By Distribution Channel

10.3.1.2.5. By End User

10.3.2. India Endometriosis Therapeutics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Endometriosis Type

10.3.2.2.2. By Diagnostic Method

10.3.2.2.3. By Therapeutic Method

10.3.2.2.4. By Distribution Channel

10.3.2.2.5. By End User

10.3.3. Japan Endometriosis Therapeutics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Endometriosis Type

10.3.3.2.2. By Diagnostic Method

10.3.3.2.3. By Therapeutic Method

10.3.3.2.4. By Distribution Channel

10.3.3.2.5. By End User

10.3.4. South Korea Endometriosis Therapeutics Market Outlook

10.3.4.1. Market Size & Forecast

10.3.4.1.1. By Value

10.3.4.2. Market Share & Forecast

10.3.4.2.1. By Endometriosis Type

10.3.4.2.2. By Diagnostic Method

10.3.4.2.3. By Therapeutic Method

10.3.4.2.4. By Distribution Channel

10.3.4.2.5. By End User

10.3.5. Australia Endometriosis Therapeutics Market Outlook

10.3.5.1. Market Size & Forecast

10.3.5.1.1. By Value

10.3.5.2. Market Share & Forecast

10.3.5.2.1. By Endometriosis Type

10.3.5.2.2. By Diagnostic Method

10.3.5.2.3. By Therapeutic Method

10.3.5.2.4. By Distribution Channel

10.3.5.2.5. By End User

11. SOUTH AMERICA ENDOMETRIOSIS THERAPEUTICS MARKET OUTLOOK

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)

11.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)

11.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)

11.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)

11.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)

11.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

11.2.6. By Country

11.3. South America: Country Analysis

11.3.1. Brazil Endometriosis Therapeutics Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Endometriosis Type

11.3.1.2.2. By Diagnostic Method

11.3.1.2.3. By Therapeutic Method

11.3.1.2.4. By Distribution Channel

11.3.1.2.5. By End User

11.3.2. Argentina Endometriosis Therapeutics Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

- 11.3.2.2. Market Share & Forecast
 - 11.3.2.2.1. By Endometriosis Type
 - 11.3.2.2.2. By Diagnostic Method
 - 11.3.2.2.3. By Therapeutic Method
 - 11.3.2.2.4. By Distribution Channel
 - 11.3.2.2.5. By End User
- 11.3.3. Colombia Endometriosis Therapeutics Market Outlook
 - 11.3.3.1. Market Size & Forecast
 - 11.3.3.1.1. By Value
 - 11.3.3.2. Market Share & Forecast
 - 11.3.3.2.1. By Endometriosis Type
 - 11.3.3.2.2. By Diagnostic Method
 - 11.3.3.2.3. By Therapeutic Method
 - 11.3.3.2.4. By Distribution Channel
 - 11.3.3.2.5. By End User

12. MIDDLE EAST AND AFRICA ENDOMETRIOSIS THERAPEUTICS MARKET OUTLOOK

- 12.1. Market Size & Forecast
 - 12.1.1. By Value
- 12.2. Market Share & Forecast
 - 12.2.1. By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics)
 - 12.2.2. By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, Others)
 - 12.2.3. By Treatment Method (Hormonal Therapy v/s Pain Management)
 - 12.2.3.1. By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, Others)
 - 12.2.4. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
 - 12.2.5. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
 - 12.2.6. By Country
- 12.3. MEA: Country Analysis
 - 12.3.1. South Africa Endometriosis Therapeutics Market Outlook
 - 12.3.1.1. Market Size & Forecast
 - 12.3.1.1.1. By Value
 - 12.3.1.2. Market Share & Forecast
 - 12.3.1.2.1. By Endometriosis Type

- 12.3.1.2.2. By Diagnostic Method
- 12.3.1.2.3. By Therapeutic Method
- 12.3.1.2.4. By Distribution Channel
- 12.3.1.2.5. By End User
- 12.3.2. UAE Endometriosis Therapeutics Market Outlook
 - 12.3.2.1. Market Size & Forecast
 - 12.3.2.1.1. By Value
 - 12.3.2.2. Market Share & Forecast
 - 12.3.2.2.1. By Endometriosis Type
 - 12.3.2.2.2. By Diagnostic Method
 - 12.3.2.2.3. By Therapeutic Method
 - 12.3.2.2.4. By Distribution Channel
 - 12.3.2.2.5. By End User
- 12.3.3. Saudi Arabia Endometriosis Therapeutics Market Outlook
 - 12.3.3.1. Market Size & Forecast
 - 12.3.3.1.1. By Value
 - 12.3.3.2. Market Share & Forecast
 - 12.3.3.2.1. By Endometriosis Type
 - 12.3.3.2.2. By Diagnostic Method
 - 12.3.3.2.3. By Therapeutic Method
 - 12.3.3.2.4. By Distribution Channel
 - 12.3.3.2.5. By End User
- 12.3.4. Egypt Endometriosis Therapeutics Market Outlook
 - 12.3.4.1. Market Size & Forecast
 - 12.3.4.1.1. By Value
 - 12.3.4.2. Market Share & Forecast
 - 12.3.4.2.1. By Endometriosis Type
 - 12.3.4.2.2. By Diagnostic Method
 - 12.3.4.2.3. By Therapeutic Method
 - 12.3.4.2.4. By Distribution Channel
 - 12.3.4.2.5. By End User
- 12.3.5. Turkey Endometriosis Therapeutics Market Outlook
 - 12.3.5.1. Market Size & Forecast
 - 12.3.5.1.1. By Value
 - 12.3.5.2. Market Share & Forecast
 - 12.3.5.2.1. By Endometriosis Type
 - 12.3.5.2.2. By Diagnostic Method
 - 12.3.5.2.3. By Therapeutic Method
 - 12.3.5.2.4. By Distribution Channel

12.3.5.2.5. By End User

13. MARKET DYNAMICS

13.1. Drivers

13.2. Challenges

14. MARKET TRENDS & DEVELOPMENTS

15. COMPETITIVE LANDSCAPE

15.1. Abbott Laboratories, Inc.

15.2. AbbVie, Inc.

15.3. Bayer AG

15.4. Pfizer, Inc.

15.5. Ipsen SA

15.6. Evotec SE

15.7. Myovant Sciences Ltd.

15.8. Philogen S.p.A.

15.9. Astellas Pharma Inc.

15.10. Orphagen Pharmaceuticals, Inc.

16. STRATEGIC RECOMMENDATIONS

I would like to order

Product name: Endometriosis Therapeutics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Endometriosis Type (Superficial Peritoneal Lesion, Endometrioma, Deeply Infiltrating Endometriosis Therapeutics), By Diagnostic Method (Ultrasound, Pelvic Examination, Laparoscopy, Magnetic Resonance Imaging, And Others), By Treatment Method (Hormonal Therapy, And Pain Management), By Drug Category (Oral Contraceptives, Progestins, NSAIDs, GnRH Analogues, And Others), By Diagnostics Type (Pure Medical Imaging, And General Laboratory Use), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By End-User, (Hospitals & Clinics, Ambulatory Care Center, And Others), By Company, By Region

Product link: <https://marketpublishers.com/r/EE52BCBBF963EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EE52BCBBF963EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970